Horizon Space Acquisition II Corp. (HSPT)

Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023
Cost of Revenue	0.45	0.2	0.01
Gross Profit	-0.45	-0.2	-0.01
Operating Income	-0.45	-0.2	-0.01
Other Non Operating Income (Expenses)	0.34	0.34	-
Pretax Income	0.62	0.14	-0.01
Net Income	0.62	0.14	-0.01
Net Income to Common	0.62	0.14	-0.01
Shares Outstanding (Basic)	4	3	2
Shares Outstanding (Diluted)	4	3	2
Shares Change (YoY)	-	49.69%	-
EPS (Basic)	0.14	0.06	-0.00
EPS (Diluted)	0.14	0.06	-0.00
EBIT	-0.45	-0.2	-0.01

Updated Dec 26, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q